Department of Surgery, Bristol Royal Infirmary, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
J Surg Oncol. 2014 Sep;110(3):313-9. doi: 10.1002/jso.23623. Epub 2014 Apr 16.
Actual long-term survival of patients with colorectal liver metastases staged by PET CT has not been reported. Objectives were to investigate whether PET CT staging results in actual improved long-term survival, to examine outcome in patients with 'equivocal' PET CT scans, and those excluded from hepatectomy by PET CT.
A retrospective analysis of patients undergoing hepatectomy for colorectal liver metastases between March 1998 and September 2008.
Overall 5- and 10-year survival was 44.8% and 23.9%. PET CT staging resulted in management changes in 23% of patients. PET CT staged patients showed significantly better survival than those staged by CT alone at 3 years (79.8% vs. 54.1%) and at 5 years (54.1% vs. 37.3%) with median survivals of 6.4 years versus 3.9 years (log rank P = 0.018). Patients with equivocal PET CT scans showed worse median survival than those with favourable PET CT (log rank P = 0.002), but may include a subpopulation whose prognosis trends towards a more favourable outcome than those excluded from liver resection by PET CT, whose median survival remains limited to 21 months.
Staging of patients with colorectal liver metastases by PET CT is associated with significantly improved actual long-term survival, and provides valuable prognostic information which guides surgical and oncological treatments.
PET CT 分期的结直肠癌肝转移患者的实际长期生存情况尚未见报道。本研究旨在探讨 PET CT 分期是否能真正改善长期生存,研究 PET CT 分期为“可疑”的患者和因 PET CT 而被排除肝切除术的患者的结局。
回顾性分析 1998 年 3 月至 2008 年 9 月期间行肝切除术治疗结直肠癌肝转移的患者。
总体 5 年和 10 年生存率分别为 44.8%和 23.9%。PET CT 分期使 23%的患者的治疗策略发生了改变。与 CT 单独分期的患者相比,PET CT 分期的患者在 3 年(79.8% vs. 54.1%)和 5 年(54.1% vs. 37.3%)时的生存率显著提高,中位生存时间分别为 6.4 年和 3.9 年(log rank P = 0.018)。PET CT 分期为“可疑”的患者的中位生存时间比 PET CT 分期为“有利”的患者差(log rank P = 0.002),但可能包括一部分预后趋势较好的患者,这些患者比因 PET CT 而被排除行肝切除术的患者的预后好,而后者的中位生存时间仍局限于 21 个月。
结直肠癌肝转移患者的 PET CT 分期与显著改善的实际长期生存相关,并提供有价值的预后信息,指导手术和肿瘤治疗。